We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
- Cancer/Oncology
-
2. Cancer vaccines
- Dr. Elias Sayour
-
3. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
5. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
6. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
- Neurology/Neuroscience
-
7. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
8. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
9. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
10. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
11. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
12. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
13. Muscarinic acetylcholine receptor modulation in neurological diseases- Prof. Andrew B. Tobin
- Immunology & Inflammation
-
14. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
15. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
16. Decoy-resistant IL18: how engineered E. coli enhances immune responses against tumors- Dr. Rizwan Romee
-
17. Transmembrane domains and the regulation of trogocytosis in T cells
- Dr. Stefano Barbera
- Infectious Diseases/Microbiology
-
20. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
22. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Pharmaceutical Sciences
-
23. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
24. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
26. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
27. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
28. The regulation of cell therapy
- Prof. Moutih Rafei
-
29. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
30. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
32. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
33. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
- Methods
-
34. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
35. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
36. MassBank development and future
- Dr. Emma L. Schymanski
-
37. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
38. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
Topics Covered
- Adjuvant
- Excipient
- Gene therapy
- Nanoparticle
- Particle size
- Production
- Solubilization
- Scaling up
Biography
Dr. Shaukat Ali is Sr. Director of Scientific Affairs and Technical Marketing at Ascendia Pharma as, with three decades of experience in the pharmaceutical industry. He has held several key roles in the industry with increasing responsibilities in the areas of synthesis, formulations and drug development. His expertise in the excipients and innovative solubilization technologies including amorphous solid dispersions, lipid based self-emulsifying drug delivery systems and lipid and polymeric nanoparticles for orals, and liposomes for parenteral delivery has led to development, and marketing of a many poorly soluble drug molecules. Dr. Ali has worked as the technical expert with a number of biopharma, ethical and generic pharma companies over the years and has helped the scientists working with innovative molecules in early phase preclinical and clinical developments of molecules across all modalities.
Dr. Ali received his PhD in Organic Chemistry from the City University of New York, NY, and carried out his postdoctoral work at the University of Minnesota and Cornell University. Dr. Ali served as a member of the editorial advisory board of American Pharma Review, Drug Development and Delivery, Contract Pharma, Biopharma Asia among others, and also serving as the Editor-In-Chief of Journal of Analytical and Pharmaceutical Research. Dr. Ali is also a member of USP Council of Expert for Excipient Test Methods committee. Dr. Ali is the recipient of IPEC Foundation’s 2020 Henk de Jong industrial research award for his contributions to formulations and excipient technologies. He has published over 60 articles in scientific journals and an inventor of several US and European patents. Dr. Ali is also an AAPS Fellow.
Talk Citation
Ali, S. (2024, March 21). Challenges and solutions of scaling up [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 4, 2026, from https://doi.org/10.69645/WOIR2470.Export Citation (RIS)
Publication History
- Published on March 21, 2024
Financial Disclosures
- Dr. Shaukat Ali has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.